Foundation Medicine ( Foundation Medicine)

Primary tabs

Foundation Medicine's picture

Management

Contact Address

About Foundation Medicine

Foundation Medicine (NASDAQ:FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer.

Foundation Medicine press release, blog etc

Tue, 02/04/2025 - 18:45 Foundation Medicine to Launch Hereditary Germline Tests, FoundationOneGermline and FoundationOneGermline More, in the United States Through a Partnership with Fulgent Genetics
Fri, 01/17/2025 - 19:17 U.S. Food and Drug Administration Approves FoundationOneCDx as a Companion Diagnostic for OJEMDA (tovorafenib) to Treat the Most Common Form of Childhood Brain Tumor in Pediatric Patients
Wed, 05/29/2024 - 16:28 Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator
Sat, 05/25/2024 - 11:00 Foundation Medicine Announces Details of Over 20 Presentations at the 2024 ASCO Annual Meeting
Thu, 05/23/2024 - 00:47 Foundation Medicine Launches RNA Sequencing Test, FoundationOneRNA, in the U.S.
Tue, 12/20/2022 - 19:02 Foundation Medicine Receives FDA Approval for FoundationOneLiquid CDx as a Companion Diagnostic for a Certain Group of Tyrosine Kinase Inhibitors for Treatment of Non-Small Cell Lung Cancer Patients
Mon, 11/14/2022 - 16:27 Foundation Medicine Launches FoundationReport+, a New Digital Reporting Experience to Streamline Precision Cancer Care
Tue, 09/20/2022 - 21:48 Foundation Medicine and Day One Biopharmaceuticals Announce Global Collaboration to Advance Pediatric Cancer Care
Mon, 09/12/2022 - 23:56 Foundation Medicine to Share 14 Abstracts at the 2022 European Society for Medical Oncology (ESMO) Congress Demonstrating the Power of Genomic Profiling to Advance Cancer Care
Sun, 09/11/2022 - 21:31 Foundation Medicine and Relay Therapeutics Collaborate to Develop FoundationOneCDx as a Companion Diagnostic for Relays Investigational FGFR2 Inhibitor, RLY-4008
Wed, 06/08/2022 - 19:37 U.S. FDA Approves FoundationOneCDx as a Companion Diagnostic for Rozlytrek (entrectinib)
Sat, 06/04/2022 - 23:06 Foundation Medicine Announces Strategic Collaboration with Arvinas
Fri, 06/03/2022 - 01:46 Foundation Medicine Partners with Lung Cancer Research Foundation and the Lung Cancer Mutation Consortium on Screening Trial to Enable Precision Therapy
Thu, 03/17/2022 - 08:36 U.S. FDA Approves FoundationOneCDx as a Companion Diagnostic for EGFR Therapeutics Targeting Exon 19 Deletions or Exon 21 Substitutions in Non-Small Cell Lung Cancer
Mon, 02/21/2022 - 18:41 U.S. FDA Approves FoundationOneCDx as a Companion Diagnostic for KEYTRUDA (pembrolizumab) to Identify Patients with Microsatellite Instability-High (MSI-H) Solid Tumors
Fri, 02/18/2022 - 05:05 Foundation Medicines ctDNA Monitoring Assay, FoundationOneTracker, Granted Breakthrough Device Designation by U.S. Food and Drug Administration
Tue, 02/08/2022 - 22:58 Foundation Medicine Announces Global Collaboration With Lilly to Develop FoundationOneCDx and FoundationOneLiquid CDx as Companion Diagnostics for RETEVMO and Loxo Oncology at Lillys Pipeline Programs
Wed, 12/08/2021 - 14:25 FoundationOneCDx Receives FDA Approval as a Companion Diagnostic for BRAF Inhibitor Therapeutics in Melanoma